机译:Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Exeter Clin Lab Int,Royal Devon & Exeter NHS Fdn Trust;
Viapath Analyt,Guys & St Thomas NHS Fdn Trust;
Exeter Inflammatory Bowel Dis & Pharmacogenet Res,Univ ExeterGastroenterol,Barts & London NHS TrustWestern Gen Hosp,NHS LothianQueen Elizabeth Univ Hosp,NHS Greater Glasgow & ClydeInfect & Immun Sci,North West London PatholBiochem,Sandwell & West Birmingham NHS TrustMetab Digest & Reprod,Imperial Coll LondonIBD Unit Gastroenterol,Hull Univ Teaching Hosp NHS TrustGastroenterol,Liverpool Univ Hosp NHS Fdn TrustGastroenterol,Guys & St Thomas Hosp NHS TrustGastroenterol,Royal Devon & Exeter NHS Fdn Trust;
CLARITY; biologic; infliximab; adalimumab; vedolizumab; COVID-19; immunosuppression; vaccination; inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; VACCINATION; TNF; MATURATION; DEFICIENT; ALPHA;